

## XVIVO Perfusion – Consensus estimates Q2 2024

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

<b>KPI (MSEK, unless otherwise specified)</b>	<b>Q2 2024E</b>
Net sales	192
Organic growth in local currency (%)	22.2
Gross profit	141
EBITDA	36
EBIT	18
Net profit	16
Earnings per share (SEK)	0.52
<b>Net sales per segment:</b>	
Thoracic	125
Abdominal	45
Services	22

XVIVO Perfusion's Q2 report will be released on Friday, 12 July, at 07:30 a.m. CEST.